126 related articles for article (PubMed ID: 36787500)
1. A Concerted Redox- and Light-Activated Agent for Controlled Multimodal Therapy against Hypoxic Cancer Cells.
Liu J; Prentice AW; Clarkson GJ; Woolley JM; Stavros VG; Paterson MJ; Sadler PJ
Adv Mater; 2023 May; 35(19):e2210363. PubMed ID: 36787500
[TBL] [Abstract][Full Text] [Related]
2. Functional Upgrading of an Organo-Ir(III) Complex to an Organo-Ir(III) Prodrug as a DNA Damage-Responsive Autophagic Inducer for Hypoxic Lung Cancer Therapy.
Wang MM; Deng DP; Zhou AM; Su Y; Yu ZH; Liu HK; Su Z
Inorg Chem; 2024 Mar; 63(10):4758-4769. PubMed ID: 38408314
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing.
Wilson WR; Pruijn FB
Clin Exp Pharmacol Physiol; 1995 Nov; 22(11):881-5. PubMed ID: 8593750
[TBL] [Abstract][Full Text] [Related]
4. Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy.
Feng L; Cheng L; Dong Z; Tao D; Barnhart TE; Cai W; Chen M; Liu Z
ACS Nano; 2017 Jan; 11(1):927-937. PubMed ID: 28027442
[TBL] [Abstract][Full Text] [Related]
5. Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
Palmer BD; van Zijl P; Denny WA; Wilson WR
J Med Chem; 1995 Mar; 38(7):1229-41. PubMed ID: 7707325
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional Theranostic Liposomes Loaded with a Hypoxia-Activated Prodrug for Cascade-Activated Tumor Selective Combination Therapy.
Dai Y; Wang B; Sun Z; Cheng J; Zhao H; Wu K; Sun P; Shen Q; Li M; Fan Q
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39410-39423. PubMed ID: 31578854
[TBL] [Abstract][Full Text] [Related]
7. Sequential Ultrasound-Triggered and Hypoxia-Sensitive Nanoprodrug for Cascade Amplification of Sonochemotherapy.
Zhuang F; Ma Q; Dong C; Xiang H; Shen Y; Sun P; Li C; Chen Y; Lu B; Chen Y; Huang B
ACS Nano; 2022 Apr; 16(4):5439-5453. PubMed ID: 35357810
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.
Palmer BD; Wilson WR; Cliffe S; Denny WA
J Med Chem; 1992 Aug; 35(17):3214-22. PubMed ID: 1507207
[TBL] [Abstract][Full Text] [Related]
9. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs.
Parker LL; Lacy SM; Farrugia LJ; Evans C; Robins DJ; O'Hare CC; Hartley JA; Jaffar M; Stratford IJ
J Med Chem; 2004 Nov; 47(23):5683-9. PubMed ID: 15509167
[TBL] [Abstract][Full Text] [Related]
10. Development and biological evaluation of AzoBGNU: A novel hypoxia-activated DNA crosslinking prodrug with AGT-inhibitory activity.
Liu Q; Wang X; Li J; Wang J; Sun G; Zhang N; Ren T; Zhao L; Zhong R
Biomed Pharmacother; 2021 Dec; 144():112338. PubMed ID: 34678728
[TBL] [Abstract][Full Text] [Related]
11. p-(Methylsulfinyl)phenyl nitrogen mustard as a novel bioreductive prodrug selective against hypoxic tumors.
Kwon CH; Blanco DR; Baturay N
J Med Chem; 1992 May; 35(11):2137-9. PubMed ID: 1597864
[No Abstract] [Full Text] [Related]
12. Setanaxib as a Potent Hypoxia-specific Therapeutic Agent Against Liver Cancer.
Owada S; Endo H; Okada C; Yoshida K; Shida Y; Tatemichi M
Anticancer Res; 2020 Sep; 40(9):5071-5079. PubMed ID: 32878795
[TBL] [Abstract][Full Text] [Related]
13. Iodinated cyanine dye-based nanosystem for synergistic phototherapy and hypoxia-activated bioreductive therapy.
Dong Y; Zhou L; Shen Z; Ma Q; Zhao Y; Sun Y; Cao J
Drug Deliv; 2022 Dec; 29(1):238-253. PubMed ID: 35001784
[TBL] [Abstract][Full Text] [Related]
14. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
[TBL] [Abstract][Full Text] [Related]
15. New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies.
Jiang GB; Zhang WY; He M; Gu YY; Bai L; Wang YJ; Yi QY; Du F
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Feb; 227():117534. PubMed ID: 31685424
[TBL] [Abstract][Full Text] [Related]
16. Programmable therapeutic nanoscale covalent organic framework for photodynamic therapy and hypoxia-activated cascade chemotherapy.
He H; Du L; Xue H; Wu J; Shuai X
Acta Biomater; 2022 Sep; 149():297-306. PubMed ID: 35811069
[TBL] [Abstract][Full Text] [Related]
17. The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells.
Fayad C; Audi H; Khnayzer RS; Daher CF
J Biol Inorg Chem; 2021 Feb; 26(1):43-55. PubMed ID: 33221954
[TBL] [Abstract][Full Text] [Related]
18. A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control.
Feng W; Gao C; Liu W; Ren H; Wang C; Ge K; Li S; Zhou G; Li H; Wang S; Jia G; Li Z; Zhang J
Chem Commun (Camb); 2016 Aug; 52(60):9434-7. PubMed ID: 27379361
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
Palmer BD; Wilson WR; Atwell GJ; Schultz D; Xu XZ; Denny WA
J Med Chem; 1994 Jul; 37(14):2175-84. PubMed ID: 8035424
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines.
Palmer BD; Wilson WR; Pullen SM; Denny WA
J Med Chem; 1990 Jan; 33(1):112-21. PubMed ID: 2296009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
